Recent Advances in Oncology Nanomedicine: Toward Novel Personalized Medicine Tools to Fight Human Cancer

Dear Colleagues,

Cancer continues to be one of the most difficult global healthcare problems. Although there is a large spectrum of drugs that can be used in therapy, the main problem is selectively killing cancer cells while reducing collateral toxicity to healthy cells. There are several biological barriers to effective drug delivery in cancer such as brain, renal, hepatic, or immune clearance. Nanoparticles loaded with drugs can be designed to overcome these biological barriers to improve efficacy while reducing morbidity. In this research avenue, next-generation nanomedicines need to be better targeted to specifically destroy cancerous tissue but face several obstacles in their clinical development, including the identification of appropriate biomarkers to target, the scale-up of synthesis, and the need to produce a reproducible effect. These hurdles need to be overcome through multidisciplinary collaborations across academia, the pharmaceutical industry, and clinicians in order to achieve the goal of eradicating cancer.

This Topical Collection of Cells is therefore dedicated to collecting multidisciplinary investigations covering cell biology and physiology, molecular biology, and biophysics expertise to provide innovative experimental preclinical proposals to the challenges of development of nanomedicines for cancer.

Dr. Sergio Comincini
Collection Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.